Acuson sells 10 echo units to Health First
Ultrasound vendor Acuson scored a coup this month when it sold 10 echocardiography systems, combined with its KinetDx PACS product, to Health First Heart Institute of Brevard, FL. Health First has installed one of Acuson’s Aspen units and
Ultrasound vendor Acuson scored a coup this month when it sold 10 echocardiography systems, combined with its KinetDx PACS product, to Health First Heart Institute of Brevard, FL. Health First has installed one of Acusons Aspen units and nine of its Sequoia C256 units, along with KinetDx, at hospitals and clinics in its network: Cape Canaveral Hospital, Palm Bay Community Hospital, Health First Healthplex Outpatient Clinic, and Holmes Regional Medical Center. The Aspen and Sequoia systems will include Acusons Imagegate hardware and software upgrade package, which it launched in September (SCAN 9/15/99).
Acuson introduced KinetDx in April at the Symposium for Computer Applications in Radiology in Houston (SCAN 5/12/99). KinetDx will link all four of Health Firsts facilities into a single network.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
